Farnesoid X Receptor Agonist Obeticholic Acid Reduces Kidney Disease in a Mouse Model of Alport Syndrome

被引：0

作者：

Jones, Bryce A. ^{[1
]}

Perry, Priscilla E. ^{[1
]}

Davidson, Shania R. ^{[1
,2
]}

Santiago, Isabel Lopez ^{[1
,3
]}

Adapa, Sharmila ^{[1
]}

Allen, Katherine C. ^{[1
]}

Dial, Katelyn ^{[1
]}

Rowland, Emma ^{[1
]}

Myakala, Komuraiah ^{[1
]}

Wang, Xiaoxin ^{[1
]}

Levi, Moshe

机构：

[1] Georgetown Univ, Med Ctr, Washington, DC 20007 USA

[2] Howard Univ, Coll Arts & Sci, Washington, DC 20059 USA

[3] Johns Hopkins Univ, Baltimore, MD USA

来源：

JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY | 2022年 / 33卷 / 11期

关键词：

D O I：

暂无

中图分类号：

R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];

学科分类号：

1002 ; 100201 ;

摘要：

FR-PO688

引用

页码：511 / 511

页数：1

共 50 条

[21] Synaptopodin deficiency exacerbates kidney disease in a mouse model of Alport syndrome
Ning, Liang
Suleiman, Hani Y.
Miner, Jeffrey H.
AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY, 2021, 321 (01) : F12 - F25
[22] KIDNEY FIBROSIS IS MITIGATED BY A DUAL ACTING FARNESOID X RECEPTOR AGONIST AND SOLUBLE EPOXIDE HYDROLASE INHIBITOR IN A MOUSE MODEL
Khan, Abdul H.
Stavniichuk, Anna
Merk, Daniel
Imig, John
JOURNAL OF INVESTIGATIVE MEDICINE, 2020, 68 (05) : 1099 - 1100
[23] The farnesoid X receptor agonist EDP-305 reduces interstitial renal fibrosis in a mouse model of unilateral ureteral obstruction
Li, Shen
Ghoshal, Sarani
Sojoodi, Mozhdeh
Arora, Gunisha
Masia, Ricard
Erstad, Derek J.
Ferriera, Diego S.
Li, Yang
Wang, Guogiang
Lanuti, Michael
Caravan, Peter
Or, Yat Sun
Jiang, Li-Juan
Tanabe, Kenneth K.
Fuchs, Bryan C.
FASEB JOURNAL, 2019, 33 (06): : 7103 - 7112
[24] The First New Trials for Primary Biliary Cirrhosis in a Decade: An International Program Evaluating the Farnesoid X Receptor Agonist Obeticholic Acid
Kowdley, Kris y
Nevens, Frederik
Andreone, Pietro
Luketic, Velimir A.
Shah, Hemant
Pencek, Richard
Marmon, Tonya K.
Shapiro, David
GASTROENTEROLOGY, 2015, 148 (04) : S991 - S992
[25] THE FIRST NEW MONOTHERAPY THERAPEUTIC PBC STUDY IN A DECADE? AN INTERNATIONAL STUDY EVALUATING THE FARNESOID X RECEPTOR AGONIST OBETICHOLIC ACID IN PBC
Jones, D.
Kowdley, K.
Chapman, R.
Burroughs, A.
Hirschfield, G.
Schramm, C.
Poupon, R.
ParEs, A.
Shapiro, D.
Pruzanski, M.
GUT, 2011, 60 : A50 - A50
[26] THE FARNESOID X RECEPTOR AGONIST, OBETICHOLIC ACID, IMPROVES INTESTINAL ANTIBACTERIAL DEFENSE AND REDUCES GUT BACTERIAL TRANSLOCATION AND HEPATIC FIBROGENESIS IN CCl4-CIRRHOTIC RATS WITH ASCITES
Ubeda, M.
Borrero, M. J.
Lario, M.
Munoz, L.
Conde, E.
Rodriguez, M.
LLedo, L.
Garcia-Bermejo, L.
Alvarez-Mon, M.
Albillos, A.
JOURNAL OF HEPATOLOGY, 2014, 60 (01) : S63 - S63
[27] Suppression of Lung Oxidative Stress, Inflammation, and Fibrosis following Nitrogen Mustard Exposure by the Selective Farnesoid X Receptor Agonist Obeticholic Acid
Meshanni, Jaclynn A.
Lee, Jordan M.
Vayas, Kinal N.
Sun, Rachel
Jiang, Chenghui
Guo, Grace L.
Gow, Andrew J.
Laskin, Jeffrey D.
Laskin, Debra L.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2024, 388 (02): : 586 - 595
[28] THE FIRST NEW MONOTHERAPY THERAPEUTIC PBC STUDY IN A DECADE? AN INTERNATIONAL STUDY EVALUATING THE FARNESOID X RECEPTOR AGONIST OBETICHOLIC ACID IN PBC
Kowdley, Kris V.
Luketic, Velimir A.
Jones, David E.
Chapman, Roger W.
Burroughs, Andrew K.
Hirschfield, Gideon M.
Poupon, Raoul
Schramm, Christoph
Vincent, Catherine
Rust, Christian
Pares, Albert
Mason, Andrew L.
Castelloe, Erin N.
Sciacca, Cathi I.
Boehm, Olaf
Pruzanski, Mark
Shapiro, David A.
HEPATOLOGY, 2011, 54 : 416A - 417A
[29] Mouse model of X-linked Alport syndrome
Rheault, MN
Kren, SM
Thielen, BK
Mesa, HA
Crosson, JT
Thomas, W
Sado, Y
Kashtan, CE
Segal, Y
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2004, 15 (06): : 1466 - 1474
[30] NBL1 Correlates with Kidney Disease in a Mouse Model for Alport Syndrome, but Is Not Causal
Willey, Courtney
Bufi, Rei
Brackett, Abigail
Sheehan, Susan Marie
Korstanje, Ron
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2024, 35 (10):

← 1 2 3 4 5 →